Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) EBT (2021 - 2025)

Historic EBT for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $51.1 million.

  • Krystal Biotech's EBT rose 518.62% to $51.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $189.5 million, marking a year-over-year increase of 9869.75%. This contributed to the annual value of $189.5 million for FY2025, which is 9869.86% up from last year.
  • Krystal Biotech's EBT amounted to $51.1 million in Q4 2025, which was up 518.62% from $48.0 million recorded in Q3 2025.
  • Krystal Biotech's EBT's 5-year high stood at $80.7 million during Q3 2023, with a 5-year trough of -$50.0 million in Q1 2022.
  • In the last 5 years, Krystal Biotech's EBT had a median value of -$7.3 million in 2021 and averaged $4.4 million.
  • As far as peak fluctuations go, Krystal Biotech's EBT crashed by 21599.42% in 2022, and later surged by 457778.97% in 2025.
  • Krystal Biotech's EBT (Quarter) stood at -$21.8 million in 2021, then crashed by 46.99% to -$32.1 million in 2022, then surged by 133.25% to $10.7 million in 2023, then soared by 356.13% to $48.6 million in 2024, then rose by 5.19% to $51.1 million in 2025.
  • Its EBT was $51.1 million in Q4 2025, compared to $48.0 million in Q3 2025 and $46.8 million in Q2 2025.